Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Effect of S-Ibuprofen Gel on Pain in Acute Soft Tissue Contusions

4 de novembro de 2026 atualizado por: Aponia Laboratories, Inc.

Randomized, Controlled, Multi-center Trial to Evaluate the Efficacy, Tolerability, and Safety of an S-Ibuprofen Gel vs. Placebo in the Local Symptomatic and Short-Term Treatment of Pain in Acute Contusions of the Soft Tissues Following Blunt Trauma

Phase 3 study designed to evaluated analgesic efficacy and safety of S-Ibuprofen Topical Gel 5%

Visão geral do estudo

Descrição detalhada

The purpose of this randomized, double-blind study is to evaluate the efficacy and safety of S-Ibuprofen Topical Gel 5% in treatment of pain in acute contusions of the soft tissues following blunt trauma.

Tipo de estudo

Intervencional

Inscrição (Estimado)

240

Estágio

  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Bonn, Alemanha, 53113
        • Recrutamento
        • Dr. med Jürgen Ulrich Schaale-Maas
        • Contato:
          • Jurgen Schaale-Maas, Dr.med.
          • Número de telefone: +49 177 7373443
          • E-mail: jschaale@icloud.com
      • Bonn, Alemanha, 53121
        • Recrutamento
        • Orthopädische Praxis-Ebert
        • Contato:
          • Eduart Ebert, Dr. med.
          • Número de telefone: +49 173 7038059
          • E-mail: ebert.e@web.de
      • Gilching, Alemanha, 82205
        • Recrutamento
        • Dr. Helmut Pabst
        • Contato:
    • Oregon
      • Bend, Oregon, Estados Unidos, 97702
        • Recrutamento
        • Northwest Foot Care - Amanda Westfall McCarty
        • Contato:
      • Bend, Oregon, Estados Unidos, 97702
        • Recrutamento
        • Northwest Foot Care - Bryan Wilhelm
        • Contato:
      • Bend, Oregon, Estados Unidos, 97702
        • Recrutamento
        • Northwest Foot Care - Hayden Bush
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 65 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Acute soft-tissue injury/contusion.
  2. Enrollment within 6 hours of the injury.
  3. Baseline NRS score for POM of injured location >5 score points on an 11-point NRS.
  4. Size of injury, as assessed by the investigator, ≥25 cm2 and ≤120 cm2
  5. Adult male or female patients aged ≥18 years.
  6. Having given written informed consent.
  7. Satisfactory health as determined by the investigator based on medical history and physical examination.

Exclusion Criteria:

  1. Significant concomitant injury in association with the acute injury; e.g., fracture, nerve injury, ligament disruption, tear of muscle or cartilage, or open wound.
  2. Excessively hairy skin at application site, cutting the hair in the injured site prior to gel application will qualify for inclusion.
  3. Current skin disorder or shaving hair at application site.
  4. History of excessive sweating/hyperhidrosis inclusive of application site.
  5. Treatment with topical or systemic NSAIDs or analgesics within 36 hours, opioids within 7 days, or corticosteroids within 60 days of inclusion in the study.
  6. Intake of long-acting NSAIDs or application of topical medication since the injury (rest-ice-compression-elevation [RICE] is allowed).
  7. Participation in a clinical study within 30 days before inclusion in the study or concomitantly.
  8. Positive drug or alcohol screen or evidence of drug or alcohol abuse in the opinion of the investigator.
  9. Pregnant or lactating or intending to become pregnant during the study.
  10. Individuals of reproductive potential who do not agree to use of an acceptable birth control method throughout the study, when engaging in any sexual activity that comes with a risk of pregnancy.
  11. History of any allergy or hypersensitivity (e.g., anaphylaxis, urticaria/hives, rhinitis, skin reaction, asthma, angioedema, or other allergic symptoms) to acetaminophen, ibuprofen, other NSAIDs, or to 1 of the excipients of the gel.
  12. History of severe cutaneous adverse reactions to any medication, such as Stevens-Johnson syndrome (SJS), erythema multiforme, toxic epidermal necrolysis (TEN), or acute generalized exanthematous pustulosis.
  13. Any ongoing condition that may interfere with the absorption, distribution, metabolism, or excretion of S-ibuprofen gel 5%.
  14. History of previous significant injury to the same extremity within 6 months.
  15. Patients with a disease affecting the same area, such as synovitis, rheumatoid arthritis, arthrosis, etc.
  16. Patients experiencing symptoms of an infectious disease including swelling of any joint of the affected area.
  17. Patients having an ongoing painful condition associated with the injury/contusion.
  18. Patients who had surgery of the affected area within 1 year of study entry.
  19. Patients with significant diseases (defined as a disease which, in the opinion of the investigator, may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study; including patients with a history of gastrointestinal bleeding, significant cardiovascular, liver, or renal disease).
  20. Patients with a blood coagulation disorder.
  21. Patients who use any impermissible medication (eg. systemic or topical NSAIDs, analgesics (other than paracetamol), opiods, corticosteroids (except for topical treatment of bronchial asthma, heparin, or psychotropic agents)
  22. Patients who participated in previous clinical studies of S-ibuprofen gel 5% and patients of the same household.
  23. Patients who are related to those persons involved directly or indirectly with the conduct of the study.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: S-Ibuprofen Topical Gel 5%

S-Ibuprofen Topical Gel 5% applied once per day to the affected injury site

Topical gel containing active ingredient S-ibuprofen

Comparador de Placebo: Vehicle Topical Gel

Placebo Gel applied once per day to the affected injury site

Placebo gel matching the active comparator in conposition and appearance without the active ingredient

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Evaluation of the efficacy of S-ibuprofen gel 5% applied once every 24 hours compared with placebo in patients with acute contusions of the soft tissues following blunt trauma
Prazo: 0-24 hours

Change from baseline/pain intensity difference of numerical rating scale (NRS) scores for pain-on-movement at 24 hours. NRS scale 0-10, 0=no pain, 10=worst possible pain.

0-24 hours

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Time to first perceptible pain relief based on direct questions to the patient and what they consider perceptible pain relief
Prazo: From time 0 every 24 hours up to 7 days

Recorded as time in minutes. Optional use of NRS scale. NRS scale 0-10, 0=no pain, 10=worst possible pain.

From time 0 every 24 hours up to 7 days
Time to onset of meaningful pain relief based on direct questions to the patient and what they consider meaningful pain relief
Prazo: From time 0 to end of study (day 7)

Recorded as time in minutes. Optional use of NRS scale. NRS scale 0-10, 0=no pain, 10=worst possible pain.

From time 0 to end of study (day 7)
Time gap between first perceptible pain relief and meaningful pain relief based on direct questions to the patient
Prazo: From time 0 to end of study (day 7)

Calculated as a difference to reach perceptible vs meaningul pain relief.

From time 0 to end of study (day 7)
Change from baseline/pain intensity difference of numerical rating scale (NRS) scores for spontaneous pain-on-movement (sPOM) at 24 hours
Prazo: At 24 hours

Recorded in patient diary based on NRS scores for sPOM at 24 hours. NRS scale 0-10, 0=no pain, 10=worst possible pain.

At 24 hours
Change from baseline for pain-at-rest (PAR) measured by numerical rating scale (NRS) at Visit 2, Visit 3, Visit 4, Visit 5, Visit 6
Prazo: At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)

Based on NRS scores for PAR at 24 hours. NRS scale 0-10, 0=no pain, 10=worst possible pain.

At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
Change from baseline for pain-on-movement (POM) measured at Visit 3, Visit 4, Visit 5, and Visit 6
Prazo: At Visit 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)

Based on NRS scores for POM. NRS scale 0-10, 0=no pain, 10=worst possible pain.

At Visit 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
Change from baseline for spontaneous pain-on-movement measured at 6 (±2), 8 (±2), 12 (±2), 16 (±2), 24 (±4), 36 (±4), 48 (±4), 60 (±4), 72 (±4), 84 (±4), 96 (±4), 120 (±4), 144 (±4), and 168 (±24) hours
Prazo: 6 (±2), 8 (±2), 12 (±2), 16 (±2), 24 (±4), 36 (±4), 48 (±4), 60 (±4), 72 (±4), 84 (±4), 96 (±4), 120 (±4), 144 (±4), and 168 (±24) hours after initial treatment administration

When possible, recorded in patient diary. NRS scale 0-10, 0=no pain, 10=worst possible pain.

6 (±2), 8 (±2), 12 (±2), 16 (±2), 24 (±4), 36 (±4), 48 (±4), 60 (±4), 72 (±4), 84 (±4), 96 (±4), 120 (±4), 144 (±4), and 168 (±24) hours after initial treatment administration
Pain-on-movement at the injured site recorded on a numerical rating scale (NRS) scale in the presence of the investigator for the timepoints at Visit 2, Visit 3, Visit 4, Visit 5, and Visit 6
Prazo: At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)

NRS scale 0-10, 0=no pain, 10=worst possible pain.

At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
Sum of pain intensity differences (SPIDs) for pain-on-movement at Visit 2, Visit 3, Visit 4, Visit 5, and Visit 6
Prazo: At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)

NRS scale 0-10, 0=no pain, 10=worst possible pain.

At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
Baseline-adjusted area under the curve (AUC) for pain-on-movement at the injured site recorded on a numerical rating scale (NRS) in the presence of the investigator for the timepoints at Visit 2, Visit 3, Visit 4, Visit 5, and Visit 6
Prazo: At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)

NRS scale 0-10, 0=no pain, 10=worst possible pain.

At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
Pain at rest measured by a numerical rating scale (NRS) at baseline at Visit 2, Visit 3, Visit 4, Visit 5, and Visit 6
Prazo: At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)

NRS scale 0-10, 0=no pain, 10=worst possible pain.

At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
Time-specific pain intensity difference for spontaneous pain-on-movement at all time points
Prazo: Time 0 to end of study (day 7)

Recorded in patient diary. Calculated from NRS scale data generated throughout the study. NRS scale 0-10, 0=no pain, 10=worst possible pain.

Time 0 to end of study (day 7)
Time-specific pain intensity difference for pain at rest at all time points
Prazo: Time 0 to end of study (day 7)

Recorded in patient diary. Calculated from NRS scale data generated throughout the study.NRS scale 0-10, 0=no pain, 10=worst possible pain.

Time 0 to end of study (day 7)
Time-specific pain intensity difference for spontaneous pain on movement at all time points
Prazo: Time 0 to end of study (day 7)

Recorded in patient diary. Calculated from NRS scale data generated throughout the study. NRS scale 0-10, 0=no pain, 10=worst possible pain.

Time 0 to end of study (day 7)
Time-specific pain intensity difference for pain at rest at all time points
Prazo: Time 0 to end of study (day 7)

Recorded in patient diary. Calculated from NRS scale data generated throughout the study. NRS scale 0-10, 0=no pain, 10=worst possible pain.

Time 0 to end of study (day 7)
Time to complete pain relief (Score = 0 pain)
Prazo: Time 0 to end of study (day 7)

NRS scale 0-10, 0=no pain, 10=worst possible pain.

Time 0 to end of study (day 7)
Time to complete resolution of pain-on-movement (Score = 0 pain)
Prazo: Time 0 to end of study (day 7)

NRS scale 0-10, 0=no pain, 10=worst possible pain.

Time 0 to end of study (day 7)
Time to complete resolution of pain at rest (Score = 0 of pain)
Prazo: Time 0 to end of study (day 7)

NRS scale 0-10, 0=no pain, 10=worst possible pain.

Time 0 to end of study (day 7)
Time to the first request of rescue medication within the first 24 hours
Prazo: Time 0 to 24 hours

If applicable

Time 0 to 24 hours
Proportion of patients taking rescue medication per dosing interval and during the entire evaluation period
Prazo: Time 0 to end of study (day 7)

If applicable

Time 0 to end of study (day 7)
Responder rate (defined as the number of patients achieving 50% reduction from baseline in the NRS score for pain-on-movement at 24 hours)
Prazo: Time 0 to 24 hours

NRS scale 0-10, 0=no pain, 10=worst possible pain.

Time 0 to 24 hours
Global efficacy assessment by investigator (5 point scale) at Visit 2, Visit 3, Visit 4, and Visit 6
Prazo: At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), and 6 (~168 hours)

5-point Likert scale. 0 = excellent, 4 = very poor

At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), and 6 (~168 hours)
Global efficacy assessments by patient (5 point scale) at Visit 2, Visit 3, Visit 4, and Visit 6
Prazo: At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), and 6 (~168 hours)

5-point Likert scale. 0 = excellent, 4 = very poor

At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), and 6 (~168 hours)
Overall dose of rescue medication
Prazo: Time 0 to end of study (Day 7)

Rescue medication use will be assessed at every visit except Visit 1

Time 0 to end of study (Day 7)
Local tolerability at every visit except V1
Prazo: Time 0 to end of study (day 7)

Examination for presence of erythema (0-3, 0 = none; 3 = severe), edema (0-3, 0 = none; 3 = severe), papiculation/vesiculation (0-3, 0 = none; 3 = severe), pruritus (NRS scale 0-10; 0 = no itch, 10 = worst possible itch), burning (NRS scale 0-10; 0 = no itch, 10 = worst possible itch)

Time 0 to end of study (day 7)
Blood pressure exam at V1 and V6
Prazo: At Visit 1 (time 0) and 6 (168 hours)

Systolic/diastolic blood pressure

At Visit 1 (time 0) and 6 (168 hours)
Adverse events at every visit
Prazo: Time 0 to end of study (day 7)
Time 0 to end of study (day 7)
Examination of pulse at V1 and V6
Prazo: At Visit 1 (time 0) and 6 (168 hours)

Pulse measured as beats per minute

At Visit 1 (time 0) and 6 (168 hours)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

8 de outubro de 2026

Conclusão Primária (Estimado)

1 de junho de 2027

Conclusão do estudo (Estimado)

1 de junho de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

25 de outubro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

4 de novembro de 2026

Primeira postagem (Real)

12 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

12 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

4 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • AP-009
  • 2025 (Concessão/Contrato do NIH dos EUA)
  • 2025-524451-31-00 (Ctis)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever